|
|
|
This is a study to investigate the potential clinical benefit of G1T48 as an oral selective estrogen receptor degrader SERD alone and in combination with palbociclib, a cyclin dependent kinase 4 6 CDK 4 6 inhibitor, in patients with estrogen receptor positive, HER2 negative metastatic breast cancer ciproflaxin |
|
发表于 2023-2-9 08:29:47
收藏
